Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04390737 · ClinicalTrials.gov registry record · Phase 1

Evaluate the Safety and Clinical Activity of HH2853

A Phase 1 study of Advanced Solid Tumor and Peripheral T-Cell Lymphoma, sponsored by Haihe Biopharma Co..

Recruiting
Registry status
Phase 1
Development phase
254
Enrollment target
20
Study locations

NCT04390737 is a Phase 1 study of Advanced Solid Tumor and Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Haihe Biopharma Co.. The registered enrollment target is 254 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04390737, a Phase 1 study of Advanced Solid Tumor and Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Haihe Biopharma Co..

RECRUITING
Registry status
Phase 1
Development phase
254 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

Conditions Studied

Advanced Solid Tumor Peripheral T-Cell Lymphoma Epithelioid Sarcoma FL Lymphoma

Interventions

  • DRUG HH2853 Tablets

Study Locations (20)

Beijing Municipality

  • Beijing Cancer Hospital - Beijing
  • Beijing Cancer Hospital - Beijing
  • Beijing Jishuitan Hospital - Beijing

Liaoning

  • Liaoning Cancer Hospital&Institute - Shenyang
  • Shengjing Hospital Of China Medical University - Shenyang

Shanghai Municipality

  • Shanghai Sixth People's Hospital - Shanghai
  • Zhongshan Hospital Fudan University - Shanghai

Arizona

  • Mayo Clinic - Phoenix

Florida

  • Mayo Clinic - Jacksonville

Minnesota

  • Mayo Clinic - Rochester

Texas

  • NEXT Oncology - San Antonio

Anhui

  • The First Affiliated Hospital of Anhui Medical University - Hefei

Trial Details

FieldValue
Enrollment Target 254 participants
Start Date 2020-09-08
Est. Completion 2028-12-31
Phase Phase 1

Sponsor

Haihe Biopharma Co.

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04390737

The ClinicalTrials.gov registry entry for NCT04390737 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (32% higher). The listed sponsor is Haihe Biopharma Co., which has 4 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which HH2853 Tablets is the first listed.

NCT04390737 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Beijing Municipality, Liaoning, Shanghai Municipality.

Frequently Asked Questions

What is clinical trial NCT04390737 about?

NCT04390737 is a clinical study titled "Evaluate the Safety and Clinical Activity of HH2853". This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.

What is the current status of trial NCT04390737?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 254 participants. The study started on 2020-09-08. Estimated completion is 2028-12-31.

What conditions does trial NCT04390737 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Peripheral T-Cell Lymphoma, Epithelioid Sarcoma, FL Lymphoma.

What interventions are being tested in trial NCT04390737?

The interventions under investigation include: HH2853 Tablets (DRUG).

Who is sponsoring clinical trial NCT04390737?

This trial is sponsored by Haihe Biopharma Co., which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04390737 being conducted?

This trial has 20 study locations across Arizona, Florida, Minnesota, Texas, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Peripheral T-Cell Lymphoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.